Cencora (COR) Stock Forecast & Price Target

Compare

1,117 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

COR Analyst Ratings

Strong Buy

10 Buy

1 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Cencora

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

COR Stock 12 Month Forecast

Average Price Target

$392.82

▲(14.54% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Cencora in the last 3 months. The average price target is $392.82 with a high forecast of $417.00 and a low forecast of $361.00. The average price target represents a 14.54% change from the last price of $342.96.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"221":"$221","418":"$418","270.25":"$270.3","319.5":"$319.5","368.75":"$368.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":417,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$417.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":392.82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$392.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":361,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$361.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[221,270.25,319.5,368.75,418],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,360.12,364.49538461538464,368.8707692307692,373.24615384615385,377.6215384615385,381.99692307692305,386.3723076923077,390.7476923076923,395.12307692307695,399.4984615384615,403.87384615384616,408.24923076923073,412.62461538461537,{"y":417,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,360.12,362.6353846153846,365.15076923076924,367.66615384615386,370.1815384615385,372.6969230769231,375.2123076923077,377.7276923076923,380.2430769230769,382.7584615384615,385.27384615384614,387.78923076923076,390.3046153846154,{"y":392.82,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,360.12,360.1876923076923,360.2553846153846,360.32307692307694,360.39076923076925,360.45846153846156,360.5261538461539,360.59384615384613,360.66153846153844,360.72923076923075,360.79692307692306,360.8646153846154,360.9323076923077,{"y":361,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":247.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222.96,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":252.26,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":252.16,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":275.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":288.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":291.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":294.3,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":287.34,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":294.36,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":311.26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":337.26,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":360.12,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$417.00

Average Price Target$392.82

Lowest Price Target$361.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Lisa Gill

J.P. Morgan

$417

Buy

21.59%

Upside

Reiterated

12/17/25

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (NYSE: IQV), Cencora (NYSE: COR) and Radnet (NASDAQ: RDNT)

Eric Coldwell

Robert W. Baird

$395→$392

Buy

14.30%

Upside

Reiterated

12/16/25

Cencora price target lowered to $392 from $395 at BairdCencora price target lowered to $392 from $395 at Baird

Allen Lutz

Bank of America Securities

$380

Hold

10.80%

Upside

Reiterated

12/15/25

Cencora's Strategic Acquisition: Hold Rating Amid Limited Near-Term Financial Upside

Glen Santangelo

Barclays

$400

Buy

16.63%

Upside

Initiated

12/08/25

Cencora initiated with an Overweight at BarclaysCencora initiated with an Overweight at Barclays

Stephen Baxter

Wells Fargo

$354→$405

Buy

18.09%

Upside

Reiterated

11/11/25

Cencora price target raised to $405 from $354 at Wells FargoCencora price target raised to $405 from $354 at Wells Fargo

Charles Rhyee

TD Cowen

$350→$400

Buy

16.63%

Upside

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Veeva Systems (NYSE: VEEV), ALX Oncology Holdings (NASDAQ: ALXO) and Cencora (NYSE: COR)

George Hill

Deutsche Bank

$322→$371

Buy

8.18%

Upside

Reiterated

11/07/25

Cencora price target raised to $371 from $322 at Deutsche BankCencora price target raised to $371 from $322 at Deutsche Bank

Kevin Caliendo

UBS

$380→$415

Buy

21.01%

Upside

Reiterated

11/07/25

Cencora's Strong Growth Potential and Market Position Justify Buy Rating and Increased Price Target

Steven Valiquette

Mizuho Securities

$340→$380

Buy

10.80%

Upside

Reiterated

11/06/25

Cencora price target raised to $380 from $340 at MizuhoCencora price target raised to $380 from $340 at Mizuho

Elizabeth Anderson CFA

Evercore ISI

$340→$400

Buy

16.63%

Upside

Reiterated

11/06/25

Analysts Offer Insights on Healthcare Companies: Cencora (NYSE: COR), Dyne Therapeutics (NASDAQ: DYN) and Enhabit, Inc (NYSE: EHAB)

Michael Cherny

Leerink Partners

$349→$361

Buy

5.26%

Upside

Reiterated

10/06/25

Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (NASDAQ: IDXX), Cencora (NYSE: COR) and Amgen (NASDAQ: AMGN)

Erin Wright

Morgan Stanley

$313→$330

Hold

-3.78%

Downside

Reiterated

07/16/25

Cencora price target raised to $330 from $313 at Morgan StanleyCencora price target raised to $330 from $313 at Morgan Stanley

Brian Tanquilut

Jefferies

$275→$300

Hold

-12.53%

Downside

Reiterated

06/30/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Biomea Fusion (NASDAQ: BMEA) and Cencora (NYSE: COR)

Daniel Grosslight

Citi

$330→$355

Buy

3.51%

Upside

Reiterated

05/08/25

Cencora price target raised to $355 from $330 at CitiCencora price target raised to $355 from $330 at Citi

David Toung

Argus Research

$270→$280

Buy

-18.36%

Downside

Reiterated

02/28/25

Cencora price target raised to $280 from $270 at ArgusCencora price target raised to $280 from $270 at Argus

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Lisa Gill

J.P. Morgan

$417

Buy

21.59%

Upside

Reiterated

12/17/25

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (NYSE: IQV), Cencora (NYSE: COR) and Radnet (NASDAQ: RDNT)

Eric Coldwell

Robert W. Baird

$395→$392

Buy

14.30%

Upside

Reiterated

12/16/25

Cencora price target lowered to $392 from $395 at BairdCencora price target lowered to $392 from $395 at Baird

Allen Lutz

Bank of America Securities

$380

Hold

10.80%

Upside

Reiterated

12/15/25

Cencora's Strategic Acquisition: Hold Rating Amid Limited Near-Term Financial Upside

Glen Santangelo

Barclays

$400

Buy

16.63%

Upside

Initiated

12/08/25

Cencora initiated with an Overweight at BarclaysCencora initiated with an Overweight at Barclays

Stephen Baxter

Wells Fargo

$354→$405

Buy

18.09%

Upside

Reiterated

11/11/25

Cencora price target raised to $405 from $354 at Wells FargoCencora price target raised to $405 from $354 at Wells Fargo

Charles Rhyee

TD Cowen

$350→$400

Buy

16.63%

Upside

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Veeva Systems (NYSE: VEEV), ALX Oncology Holdings (NASDAQ: ALXO) and Cencora (NYSE: COR)

George Hill

Deutsche Bank

$322→$371

Buy

8.18%

Upside

Reiterated

11/07/25

Cencora price target raised to $371 from $322 at Deutsche BankCencora price target raised to $371 from $322 at Deutsche Bank

Kevin Caliendo

UBS

$380→$415

Buy

21.01%

Upside

Reiterated

11/07/25

Cencora's Strong Growth Potential and Market Position Justify Buy Rating and Increased Price Target

Steven Valiquette

Mizuho Securities

$340→$380

Buy

10.80%

Upside

Reiterated

11/06/25

Cencora price target raised to $380 from $340 at MizuhoCencora price target raised to $380 from $340 at Mizuho

Elizabeth Anderson CFA

Evercore ISI

$340→$400

Buy

16.63%

Upside

Reiterated

11/06/25

Analysts Offer Insights on Healthcare Companies: Cencora (NYSE: COR), Dyne Therapeutics (NASDAQ: DYN) and Enhabit, Inc (NYSE: EHAB)

Michael Cherny

Leerink Partners

$349→$361

Buy

5.26%

Upside

Reiterated

10/06/25

Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (NASDAQ: IDXX), Cencora (NYSE: COR) and Amgen (NASDAQ: AMGN)

Erin Wright

Morgan Stanley

$313→$330

Hold

-3.78%

Downside

Reiterated

07/16/25

Cencora price target raised to $330 from $313 at Morgan StanleyCencora price target raised to $330 from $313 at Morgan Stanley

Brian Tanquilut

Jefferies

$275→$300

Hold

-12.53%

Downside

Reiterated

06/30/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Biomea Fusion (NASDAQ: BMEA) and Cencora (NYSE: COR)

Daniel Grosslight

Citi

$330→$355

Buy

3.51%

Upside

Reiterated

05/08/25

Cencora price target raised to $355 from $330 at CitiCencora price target raised to $355 from $330 at Citi

David Toung

Argus Research

$270→$280

Buy

-18.36%

Downside

Reiterated

02/28/25

Cencora price target raised to $280 from $270 at ArgusCencora price target raised to $280 from $270 at Argus

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cencora

1 Month

xxx

Success Rate

12/21 ratings generated profit

Average Return

+3.09%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +3.09% per trade.

3 Months

xxx

Success Rate

15/21 ratings generated profit

Average Return

+6.47%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +6.47% per trade.

1 Year

Elizabeth Anderson CFAEvercore ISI

Success Rate

20/21 ratings generated profit

Average Return

+23.67%

reiterated a buy rating last month

Copying Elizabeth Anderson CFA's trades and holding each position for 1 Year would result in 95.24% of your transactions generating a profit, with an average return of +23.67% per trade.

2 Years

xxx

Success Rate

20/21 ratings generated profit

Average Return

+43.24%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 95.24% of your transactions generating a profit, with an average return of +43.24% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

COR Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, COR has received 18 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. COR average Analyst price target in the past 3 months is 392.82.

Each month's total comprises the sum of three months' worth of ratings.

COR Financial Forecast

COR Earnings Forecast

Next quarter’s earnings estimate for COR is $4.04 with a range of $3.89 to $4.39. The previous quarter’s EPS was $3.84. COR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year COR has Performed in-line its overall industry.

COR Sales Forecast

Next quarter’s sales forecast for COR is $86.02B with a range of $84.69B to $87.64B. The previous quarter’s sales results were $83.73B. COR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year COR has Performed in-line its overall industry.

COR Stock Forecast FAQ

What is COR’s average 12-month price target, according to analysts?

Based on analyst ratings, Cencora’s 12-month average price target is 392.82.

What is COR’s upside potential, based on the analysts’ average price target?

Cencora has 14.54% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is COR a Buy, Sell or Hold?

Cencora has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.

What is Cencora’s price target?

The average price target for Cencora is 392.82. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $417.00 ,the lowest forecast is $361.00. The average price target represents 14.54% Increase from the current price of $342.96.

What do analysts say about Cencora?

Cencora’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of COR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Cencora (COR) Stock Forecast & Price Target

COR Analyst Ratings

COR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cencora

COR Analyst Recommendation Trends

COR Financial Forecast

COR Earnings Forecast

COR Sales Forecast

COR Stock Forecast FAQ

Detailed List of Analyst Forecasts